[go: up one dir, main page]

PE20091344A1 - Arilindenopirimidinas como antagonistas del receptor a2a de adenosina - Google Patents

Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Info

Publication number
PE20091344A1
PE20091344A1 PE2008001819A PE2008001819A PE20091344A1 PE 20091344 A1 PE20091344 A1 PE 20091344A1 PE 2008001819 A PE2008001819 A PE 2008001819A PE 2008001819 A PE2008001819 A PE 2008001819A PE 20091344 A1 PE20091344 A1 PE 20091344A1
Authority
PE
Peru
Prior art keywords
disease
adenosine
receptor
arylindenopyrimidines
antagonists
Prior art date
Application number
PE2008001819A
Other languages
English (en)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20091344A1 publication Critical patent/PE20091344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULA A, SOLVATOS, HIDRATOS, TAUTOMEROS Y SUS SALES. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR A2A DE ADENOSINA. SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDAD DE PARKINSON, MAL DE HUNTINGTON, ATROFIAS DE SISTEMAS MULTIPLES, DEGENERACION CORTICOBASAL, ENFERMEDAD DE ALZHEIMER, DEMENCIA SENIL, ENTRE OTROS
PE2008001819A 2007-10-24 2008-10-23 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina PE20091344A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24

Publications (1)

Publication Number Publication Date
PE20091344A1 true PE20091344A1 (es) 2009-09-24

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001819A PE20091344A1 (es) 2007-10-24 2008-10-23 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Country Status (12)

Country Link
US (1) US8017614B2 (es)
EP (1) EP2217575A1 (es)
JP (1) JP2011500819A (es)
CN (1) CN101835759A (es)
AR (1) AR069009A1 (es)
AU (1) AU2008317034A1 (es)
CL (1) CL2008003131A1 (es)
PA (1) PA8801501A1 (es)
PE (1) PE20091344A1 (es)
TW (1) TW200934493A (es)
UY (1) UY31420A1 (es)
WO (1) WO2009055308A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
EP2838530B1 (en) 2012-04-20 2017-04-05 UCB Biopharma SPRL Methods for treating parkinson's disease
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
TW200934493A (en) 2009-08-16
AR069009A1 (es) 2009-12-23
US20090111827A1 (en) 2009-04-30
EP2217575A1 (en) 2010-08-18
US8017614B2 (en) 2011-09-13
PA8801501A1 (es) 2009-05-15
CN101835759A (zh) 2010-09-15
UY31420A1 (es) 2009-04-30
WO2009055308A1 (en) 2009-04-30
JP2011500819A (ja) 2011-01-06
CL2008003131A1 (es) 2010-02-19
AU2008317034A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
AR058807A1 (es) 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
NI201300068A (es) Moduladores del receptor de glucagón
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CU23824A3 (es) Compuestos tricíclicos y sus composiciones
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY30835A1 (es) 8-alquinilxantinas y derivados
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR078434A1 (es) Sales de tetrazol-1-il- fenoximetil-tiazol-2-il- piperinidil- pirimidina sustituida
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PE20091344A1 (es) Arilindenopirimidinas como antagonistas del receptor a2a de adenosina
CR10963A (es) Compuestos de 2-amino pirimidina
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
UY30558A1 (es) Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
CL2016001348A1 (es) Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros

Legal Events

Date Code Title Description
FC Refusal